转移性乳腺癌一线抗HER2治疗放射学完全缓解的临床病理预测因素
Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer.
作者信息
Cucciniello Linda, Blondeaux Eva, Bighin Claudia, Gasparro Simona, Russo Stefania, Dri Arianna, Pugliese Palma, Fontana Andrea, Cortesi Enrico, Ferzi Antonella, Riccardi Ferdinando, Sini Valentina, Boni Luca, Fabi Alessandra, Montemurro Filippo, De Laurentiis Michelino, Arpino Grazia, Del Mastro Lucia, Gerratana Lorenzo, Puglisi Fabio
机构信息
Department of Medicine, University of Udine, 33100, Udine, Italy.
Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, 33081, Aviano, Italy.
出版信息
NPJ Breast Cancer. 2024 Dec 18;10(1):105. doi: 10.1038/s41523-024-00713-8.
This study aimed to identify the clinico-pathological variables predictive of radiologic complete response (rCR) to first-line anti-HER2 therapy in patients with HER2-positive metastatic breast cancer. Patients were selected from the database of the GIM14 study and classified according to the best radiologic response obtained to first-line anti-HER2 therapy and upon time-to-treatment-discontinuation (TTD). A total of 545 patients were included in the analysis. Eighty patients experienced a rCR to first-line anti-HER2 therapy with a TTD > 3 months and HER2 Immunohistochemistry score 3+, presence of non-visceral metastases and 1 metastatic site were significantly associated with higher odds of obtaining a CR. Of the 80 patients achieving a rCR, 56 experienced a CR with a TTD > 18 months, with anti-HER2 therapy being the only variable significantly associated with a higher probability of achieving such sustained CR.
本研究旨在确定可预测HER2阳性转移性乳腺癌患者一线抗HER2治疗后放射学完全缓解（rCR）的临床病理变量。患者选自GIM14研究数据库，并根据一线抗HER2治疗获得的最佳放射学反应以及治疗中断时间（TTD）进行分类。共有545例患者纳入分析。80例患者一线抗HER2治疗后出现rCR，TTD＞3个月，HER2免疫组化评分3+、无内脏转移以及1个转移部位与获得CR的较高几率显著相关。在80例实现rCR的患者中，56例TTD＞18个月时出现CR，抗HER2治疗是与实现这种持续CR的较高概率显著相关的唯一变量。
Zotero 插件